Verona Pharma plc
VRNA
Pozycja w akcjach
#2205
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Cena akcji
$106.91
Ostatnia synchronizacja: 2025-10-07
Kapitalizacja rynkowa
$9.09B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
GB
Handel Verona Pharma plc (VRNA)
Kategoria
Healthcare
Historia ceny akcji dla Verona Pharma plc (VRNA)
Najwyższa cena zamknięcia: $106.85 dnia 2025-10-01
Najniższa cena zamknięcia: $13.50 dnia 2017-04-01
Najniższa cena zamknięcia: $13.50 dnia 2017-04-01
Historia cen akcji firmy Verona Pharma plc od 2017 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2025 | 154.19% |
| 2024 | 157.60% |
| 2023 | -2.67% |
| 2022 | 215.71% |
| 2021 | -30.29% |
| 2020 | 68.43% |
| 2019 | -55.34% |
| 2018 | -13.21% |
| 2017 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.09 | -4.30% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
